Premium
Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy ( PPCM )
Author(s) -
Sliwa Karen,
Mebazaa Alexandre,
HilfikerKleiner Denise,
Petrie Mark C.,
Maggioni Aldo P.,
Laroche Cecile,
RegitzZagrosek Vera,
Schaufelberger Maria,
Tavazzi Luigi,
van der Meer Peter,
RoosHesselink Jolien W.,
Seferovic Petar,
van SpandonckZwarts Karin,
Mbakwem Amam,
Böhm Michael,
Mouquet Frederic,
Pieske Burkert,
Hall Roger,
Ponikowski Piotre,
Bauersachs Johann
Publication year - 2017
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1002/ejhf.780
Subject(s) - medicine , peripartum cardiomyopathy , heart failure , ivabradine , digoxin , cardiology , pediatrics , cardiomyopathy , heart rate , blood pressure
Abstract Aims The purpose of this study is to describe disease presentation, co‐morbidities, diagnosis and initial therapeutic management of patients with peripartum cardiomyopathy ( PPCM ) living in countries belonging to the European Society of Cardiology ( ESC ) vs. non‐ ESC countries. Methods and results Out of 500 patients with PPCM entered by 31 March 2016, we report on data of the first 411 patients with completed case record forms (from 43 countries) entered into this ongoing registry. There were marked differences in socio‐demographic parameters such as Human Development Index, GINI index on inequality, and Health Expenditure in PPCM patients from ESC vs. non‐ ESC countries ( P < 0.001 each). Ethnicity was Caucasian (34%), Black African (25.8%), Asian (21.8%), and Middle Eastern backgrounds (16.4%). Despite the huge disparities in socio‐demographic factors and ethnic backgrounds, baseline characteristics are remarkably similar. Drug therapy initiated post‐partum included ACE inhibitors/ ARBs and mineralocorticoid receptor antagonists with identical frequencies in ESC vs. non‐ ESC countries. However, in non‐ ESC countries, there was significantly less use of beta‐blockers (70.3% vs. 91.9%) and ivabradine (1.4% vs. 17.1%), but more use of diuretics (91.3% vs. 68.8%), digoxin (37.0% vs. 18.0%), and bromocriptine (32.6% vs. 7.1%) ( P < 0.001). More patients in non‐ ESC vs. ESC countries continued to have symptomatic heart failure after 1 month (92.3% vs. 81.3%, P < 0.001). Venous thrombo‐embolic events, arterial embolizations, and cerebrovascular accidents were documented in 28 of 411 patients (6.8%). Neonatal death rate was 3.1%. Conclusion PPCM occurs in women from different ethnic backgrounds globally. Despite marked differences in socio‐economic background, mode of presentation was largely similar. Embolic events and persistent heart failure were common within 1 month post‐diagnosis and required intensive, multidisciplinary management.